Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. ('Visara'), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol 'NBP'), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, […]